Filing Flows › Coherus Oncology (CHRS) › R&D spending
Coherus Oncology (CHRS) R&D spending by quarter
Coherus Oncology's R&D spending was $21.4M in Q2 2026 (second quarter 2026), -0.5% from Q1 2026. Over the last 7 quarters it ranged from $20.8M (Q4 2024) to $31.0M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $21.4M | -0.5% | -18% |
| Q1 2026 | $21.5M | -30% | -12% |
| Q4 2025 | $31.0M | +14% | +49% |
| Q3 2025 | $27.3M | +4% | — |
| Q2 2025 | $26.3M | +8% | — |
| Q1 2025 | $24.4M | +17% | — |
| Q4 2024 | $20.8M | — | — |
Q2 2026 at a glance
Coherus Oncology, Q2 2026: revenue $14.3M (+40% year over year), operating margin -226.0%, net loss $20.6M, operating cash flow −$62.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Coherus Oncology's R&D spending?
Coherus Oncology's R&D spending was $21.4M in Q2 2026 (second quarter 2026), -0.5% from Q1 2026.
How has Coherus Oncology's R&D spending changed?
Over the last 7 quarters it ranged from $20.8M (Q4 2024) to $31.0M (Q4 2025).